WO2001010446A2 - Formulations for parenteral use of estramustine phosphate and albumin - Google Patents

Formulations for parenteral use of estramustine phosphate and albumin Download PDF

Info

Publication number
WO2001010446A2
WO2001010446A2 PCT/EP2000/007678 EP0007678W WO0110446A2 WO 2001010446 A2 WO2001010446 A2 WO 2001010446A2 EP 0007678 W EP0007678 W EP 0007678W WO 0110446 A2 WO0110446 A2 WO 0110446A2
Authority
WO
WIPO (PCT)
Prior art keywords
estramustine phosphate
human albumin
cancer
formulation according
formulation
Prior art date
Application number
PCT/EP2000/007678
Other languages
French (fr)
Other versions
WO2001010446A3 (en
Inventor
Lorena Muggetti
Paolo Colombo
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia & Upjohn S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918779.1A external-priority patent/GB9918779D0/en
Priority claimed from IT1999MI001998 external-priority patent/IT1313629B1/en
Priority to SK178-2002A priority Critical patent/SK1782002A3/en
Priority to EP00949471A priority patent/EP1206266A2/en
Priority to JP2001514963A priority patent/JP2003506408A/en
Priority to KR1020027001700A priority patent/KR20020019967A/en
Priority to MXPA02001395A priority patent/MXPA02001395A/en
Priority to HU0202645A priority patent/HUP0202645A3/en
Application filed by Pharmacia & Upjohn S.P.A. filed Critical Pharmacia & Upjohn S.P.A.
Priority to AU62809/00A priority patent/AU6280900A/en
Priority to CA002380312A priority patent/CA2380312A1/en
Priority to BR0013276-4A priority patent/BR0013276A/en
Priority to NZ517632A priority patent/NZ517632A/en
Priority to IL14774500A priority patent/IL147745A0/en
Priority to EA200200234A priority patent/EA200200234A1/en
Publication of WO2001010446A2 publication Critical patent/WO2001010446A2/en
Publication of WO2001010446A3 publication Critical patent/WO2001010446A3/en
Priority to NO20020631A priority patent/NO20020631D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to pharmaceutical formulations of estramustine phosphate for parenteral use and, more particularly, to formulations of estramustine phosphate for parenteral use further comprising human albumin.
  • Estramustine phosphate (The Merck Index, XII Ed., No. 3749, 1996) is an estradiol-17 ⁇ -phosphate derivative widely known in the art as antitumor agent, currently used in the treatment of advanced adenocarcinoma of the prostate.
  • the drug is usually administered orally, preferably at a dose of 10-15 mg/kg/day.
  • Intravenous administration is also adopted in some particular cases.
  • initial intravenous administration of estramustine phosphate, followed by oral administration has been reported at dosages paralleling the oral administration for the drug, i.e. 300-600 mg daily given intravenously and usually repetitively over for several consecutive days (see, for a reference, British Journal of Urology, 1977, 49, 73-79; J. Urol .108 : 303-306 , 1972; Eur. Clin. Pharmacol. 26(1), 113-119, 1984; Eur. Urol. 1990, 17, 216-218) .
  • Estramustine phosphate as well as other well-known cytotoxic compounds used in antitumor therapy are known to cause, or potentially cause, vascular damages at the site of injection when parenterally, in particular intravenously, administered.
  • cyclodextrins in the preparation of formulations for parenteral administration of cytotoxic known to cause ulcerative lesions. See, for a reference, US patent No. 5,804,568 in the name of Supergen Inc.
  • estramustine phosphate containing human albumin also known in the art are formulations for the intravenous administration of estramustine phosphate containing human albumin, reported to be characterised by fewer local side- effects upon injection of the active (see, for a reference, H. Schutz et al . ; Whypharmazie, II year, issue No. 3, 1988) .
  • formulations for parenteral use comprising estramustine phosphate together with human albumin which, unexpectedly, resulted to achieve optimal protection from side-effects even at lower concentrations of human albumin, with respect to the active, compared to the albumin concentration of the prior art formulations .
  • estramustine phosphate in admixture with human albumin, wherein the weight ratio between estramustine phosphate and human albumin is from about 1:5 to about 1:0.3, respectively.
  • the formulations object of the present invention do not provoke ulcerative damages, nor thrombophlebitis, at the site of injection.
  • estramustine phosphate as the active ingredient, we intend any formulation comprising estramustine phosphate either in the acid form or as a pharmaceutically acceptable salt for parenteral administration such as, for instance, a salt with a basic amino acid or with N-methyl glucamine, otherwise referred to as meglu ine .
  • estramustine phosphate is in the form of its meglumine salt.
  • the above formulations are advantageously used for intravenous use.
  • these formulations can be administered to patients either as a slow injection, e.g. over about 30 minutes to about 3 hours, or as a bolus injection, also referred to as IV (intravenous) push.
  • IV intravenous
  • the formulations object of the present invention comprise estramustine phosphate in admixture with human albumin wherein the weight ratio between estramustine phosphate and human albumin is from about 1:4 to about 1:0.4, respectively.
  • the said weight ratio between estramustine phosphate and human albumin is from about 1:1 to about 1:0.5, respectively.
  • the formulations of the invention provide a very advantageous method for delivering estramustine phosphate intravenously, even when high doses of the active are needed.
  • estramustine phosphate as a single infusion dosage of the active exceeding 1300 mg, in admixture with human albumin, wherein the weight ratio between estramustine phosphate and human albumin is from about 1:5 to about 1:0.3, respectively.
  • a formulation for parenteral use comprising estramustine phosphate, as a single infusion dosage of the active exceeding 950 mg/m 2 , in admixture with human albumin, wherein the weight ratio between estramustine phosphate and human albumin is from about 1:5 to about 1:0.3, respectively.
  • the formulations object of the present invention allow the administration of the active either as a single agent or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, e.g. aromatase inhibitors, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g.
  • COX-2 inhibitors COX-2 inhibitors
  • metallomatrixprotease inhibitors telomerase inhibitors
  • tyrosine kinase inhibitors anti-growth factor receptor agents
  • anti-HER agents anti-EGFR agents
  • anti- angiogenesis agents farnesyl transferase inhibitors
  • ras- raf signal transduction pathway inhibitors cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
  • the above formulations can be administered in combination with one or more chemotherapeutic agents, optionally within liposomal formulations thereof.
  • chemotherapeutic agents are, for instance, taxane, taxane derivatives, CPT-11, camptothecin and derivatives thereof, anthracycline glycosides, e.g. doxorubicin, idarubicin or epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin and the like, optionally within liposomal formulations thereof.
  • the above formulations can be also administered in combination with protein kinase inhibitors such as, for instance, the indolinone derivatives disclosed by Sugen in the international patent applications WO 96/40116 and WO 99/61422, which are herewith incorporated by reference.
  • the formulations object of the invention can be preferably administered in combination with 3- [4- (2- carboxyethyl-3 , 5-dimethylpyrrol-2-yl)methylidenyl] -2- indolinone and 3 [ (2 , 4-dimethylpyrrol-5-yl)methylidenyl] -2- indolinone, better known as Sugen SU 6668 and SU 5416, respectively .
  • the formulations of the invention may be administered sequentially with known anticancer agents when a combination formulation is inappropriate.
  • estramustine phosphate in admixture with human albumin, wherein the weight ratio between estramustine phosphate and human albumin is from about 1:5 to about 1:0.3, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy .
  • estramustine phosphate was dissolved in different vehicles such as water solution for injection and water solution for injection further containing different amounts of human albumin.
  • the following solutions of estramustine phosphate human albumin in a weight ratio of 1:3.3 and of 1:0.8, were prepared and tested.
  • Estramustine phosphate in the form of meglumine salt, was administered to groups of rats as a repeated intravenous injection during 3 days. Rats were then sacrificed: a half of the rats at the fourth day and a half at the fifth day. The dose level of estramustine phosphate, in all the different tested solutions, was of 150 mg/kg/day. Clinical observations were recorded daily. Thrombophlebitic side effects resulted in a dark bluish/blackish coloration of the tail during the treatment period.
  • a score system based on tail coloration and its extension was used to evaluate the different tested formulations.
  • the score system considered estramustine phosphate water solution as the positive control (i.e. marked toxicity) .
  • Water for injection was administered to the control group as negative control (i.e. no toxicity signs).
  • Estramustine phosphate in a water solution induced, at the used dose, local irritant effects at the injection site after the first administration and marked toxicity signs at the end of the experiment.
  • Albumin containing formulations showed no toxicity signs even when albumin was present at very low concentrations. Histological evaluation of the tail of the rats treated with the formulations containing albumin did not reveal any damage when compared to the tails of the control group.
  • estramustine phosphate in a water solution containing human albumin induced markedly less local irritant effects when compared with a water solution of the same.
  • One particularly preferred schedule for administering the formulation of estramustine phosphate according to the invention is a single infusion given once weekly to a maximal dose of 4000 mg or 3500 mg/m 2 .
  • Another preferred schedule is the administration of a single drug infusion once every two to four weeks .
  • One schedule may be preferred over another in consideration of schedules with other optional concomitant therapy. These schedules may repeat in serial or as repetitive fashion.
  • the formulations of the present invention are useful in antitumor therapy, particularly in the treatment of prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer and cancers of the brain.
  • the formulations object of the present invention are prepared according to conventional techniques adopted in the preparation of pharmaceutical forms for parenteral use.
  • a proper amount of estramustine phosphate either as a dry powder or into a lyophilised form, is dissolved in a pharmaceutically acceptable solution for parenteral use and then admixed with a proper amount of human albumin, either as a dry powder or as a commercially available solution, e.g. human albumin 25%, 20% or 5%, optionally properly diluted.
  • estramustine phosphate in the form of a suitable salt such as, for instance, N-methyl glucamine salt
  • a suitable amount of sterile water or aqueous dextrose solution e.g. 5% dextrose in water for intravenous administration
  • a proper amount of powdered human albumin e.g. 5% dextrose in water for intravenous administration
  • the above admixture is then stirred, sterilised, and subsequently lyophilised according to conventional techniques .
  • the freeze-dried formulation is prepared and stored in vials for injection; the addition of a proper amount of sterile water or of a physiological solution for parenteral use enables the preparation of the final formulation to be injected.
  • estramustine phosphate for instance as N-methyl-glucamine salt and under lyophilized form, is added to a proper amount of water or of a physiological solution for parenteral use already containing human albumin.
  • the preparation of the final formulation to be injected is prepared just before its use, by reconstituting the lyophilized form containing the active principle, for instance estramustine phosphate N-methyl- glucamine salt, in the presence of a physiological solution for parenteral use containing a proper amount of human albumin.
  • the active principle for instance estramustine phosphate N-methyl- glucamine salt
  • estramustine phosphate or salts thereof under lyophilized form, and a physiological solution for parenteral use containing human albumin.
  • the above methods are also suitable for preparing high dosages estramustine phosphate formulations whilst maintaining the desired weight ratio between the components .
  • the unit strength of the formulation to be injected depended on the concentration of the active in the solution itself and, of course, on the filling volume of the vials used to prepare the final formulation.
  • formulations of the present invention may optionally contain pharmaceutically acceptable excipients for parenteral administration such as, for instance, bulking agents, e.g. lactose or mannitol, pH buffering agents, anti-oxidant agents, preservative agents, tonicity adjusters and the like.
  • pharmaceutically acceptable excipients for parenteral administration such as, for instance, bulking agents, e.g. lactose or mannitol, pH buffering agents, anti-oxidant agents, preservative agents, tonicity adjusters and the like.
  • the obtained solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 100 mg/ml of human albumin (1:3.3 weight ratio respectively).
  • Example 1 The formulation described in Example 1 was also prepared by dissolving the commercially available Estracyt ® freeze- dried formulation containing 300 mg/vial of the active. The reconstitution of the formulation was made by using 10 ml of a 100 mg/ml human albumin solution so as to obtain a final concentration of 30 mg/ml of estramustine phosphate and 100 mg/ml of human albumin (1:3.3 weight ratio respectively) .
  • the albumin solution could be prepared either by dissolving in water a proper amount of human albumin as a dry powder or by properly diluting a commercially available human albumin solution.
  • the obtained solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 25 mg/ml of human albumin (1:0.8 weight ratio respectively).
  • Example 4 The formulation described in Example 3 was also prepared by dissolving the commercially available Estracyt ® freeze- dried formulation containing 300 mg/vial of the active. The reconstitution of the formulation was made by using 10 ml of a 25 mg/ml human albumin solution so as to obtain a final concentration of 30 mg/ml of estramustine phosphate and 25 mg/ml of human albumin (1:0.8 weight ratio respectively) .
  • the albumin solution could be prepared either by dissolving in water a proper amount of human albumin as a dry powder or by properly diluting a commercially available human albumin solution.

Abstract

A pharmaceutical formulation which comprises a parenterally acceptable carrier or a diluent and estramustine phosphate in admixture with human albumin, wherein the weight ratio of estramustine phosphate to human albumin is from about 1:5 to about 1:0.3. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustine phosphate to be administered with no side effects at the side of injection.

Description

FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE AND ALBUMIN
The present invention relates to pharmaceutical formulations of estramustine phosphate for parenteral use and, more particularly, to formulations of estramustine phosphate for parenteral use further comprising human albumin.
Estramustine phosphate (The Merck Index, XII Ed., No. 3749, 1996) is an estradiol-17β-phosphate derivative widely known in the art as antitumor agent, currently used in the treatment of advanced adenocarcinoma of the prostate.
The drug is usually administered orally, preferably at a dose of 10-15 mg/kg/day. Intravenous administration, however, is also adopted in some particular cases. For example, initial intravenous administration of estramustine phosphate, followed by oral administration, has been reported at dosages paralleling the oral administration for the drug, i.e. 300-600 mg daily given intravenously and usually repetitively over for several consecutive days (see, for a reference, British Journal of Urology, 1977, 49, 73-79; J. Urol .108 : 303-306 , 1972; Eur. Clin. Pharmacol. 26(1), 113-119, 1984; Eur. Urol. 1990, 17, 216-218) .
Estramustine phosphate as well as other well-known cytotoxic compounds used in antitumor therapy are known to cause, or potentially cause, vascular damages at the site of injection when parenterally, in particular intravenously, administered.
As an example, studies in patients treated with estramustine phosphate administered as a slow intravenous injection or as a bolus, at 300 mg/day, revealed thrombophlebitis and local irritations at the peripheral intravenous injection sites.
These drawbacks are considered major limitations for the intravenous administration of estramustine phosphate, thus requiring, in many patients, the establishment of central line administration or, in some cases, even discontinuation of the treatment.
With the aim of minimising the unwanted effects associated with the intravenous administration of cytotoxic agents, a few means are reported in the art.
Among them is the use of cyclodextrins in the preparation of formulations for parenteral administration of cytotoxic known to cause ulcerative lesions. See, for a reference, US patent No. 5,804,568 in the name of Supergen Inc.
Also known in the art are formulations for the intravenous administration of estramustine phosphate containing human albumin, reported to be characterised by fewer local side- effects upon injection of the active (see, for a reference, H. Schutz et al . ; Krankenhauspharmazie, II year, issue No. 3, 1988) .
In this respect, we found formulations for parenteral use comprising estramustine phosphate together with human albumin which, unexpectedly, resulted to achieve optimal protection from side-effects even at lower concentrations of human albumin, with respect to the active, compared to the albumin concentration of the prior art formulations .
It is therefore the object of the present invention a formulation for parenteral use comprising estramustine phosphate in admixture with human albumin, wherein the weight ratio between estramustine phosphate and human albumin is from about 1:5 to about 1:0.3, respectively.
Once administered intravenously to patients, the formulations object of the present invention do not provoke ulcerative damages, nor thrombophlebitis, at the site of injection.
In the present invention, unless otherwise specified, with the term formulation comprising estramustine phosphate, as the active ingredient, we intend any formulation comprising estramustine phosphate either in the acid form or as a pharmaceutically acceptable salt for parenteral administration such as, for instance, a salt with a basic amino acid or with N-methyl glucamine, otherwise referred to as meglu ine .
Preferably, estramustine phosphate is in the form of its meglumine salt.
According to a preferred embodiment of the invention, the above formulations are advantageously used for intravenous use.
As such, these formulations can be administered to patients either as a slow injection, e.g. over about 30 minutes to about 3 hours, or as a bolus injection, also referred to as IV (intravenous) push.
Preferably, the formulations object of the present invention comprise estramustine phosphate in admixture with human albumin wherein the weight ratio between estramustine phosphate and human albumin is from about 1:4 to about 1:0.4, respectively.
Even more preferably, the said weight ratio between estramustine phosphate and human albumin is from about 1:1 to about 1:0.5, respectively.
In addition, in view of the low amount of required albumin, the formulations of the invention provide a very advantageous method for delivering estramustine phosphate intravenously, even when high doses of the active are needed.
It is therefore a further object of the invention a formulation for parenteral use comprising estramustine phosphate, as a single infusion dosage of the active exceeding 1300 mg, in admixture with human albumin, wherein the weight ratio between estramustine phosphate and human albumin is from about 1:5 to about 1:0.3, respectively. According to another preferred embodiment of the invention, it is further provided a formulation for parenteral use comprising estramustine phosphate, as a single infusion dosage of the active exceeding 950 mg/m2, in admixture with human albumin, wherein the weight ratio between estramustine phosphate and human albumin is from about 1:5 to about 1:0.3, respectively.
The formulations object of the present invention allow the administration of the active either as a single agent or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, e.g. aromatase inhibitors, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), metallomatrixprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti- angiogenesis agents, farnesyl transferase inhibitors, ras- raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
As an example, the above formulations can be administered in combination with one or more chemotherapeutic agents, optionally within liposomal formulations thereof. Examples of chemotherapeutic agents are, for instance, taxane, taxane derivatives, CPT-11, camptothecin and derivatives thereof, anthracycline glycosides, e.g. doxorubicin, idarubicin or epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin and the like, optionally within liposomal formulations thereof. In addition, the above formulations can be also administered in combination with protein kinase inhibitors such as, for instance, the indolinone derivatives disclosed by Sugen in the international patent applications WO 96/40116 and WO 99/61422, which are herewith incorporated by reference. In this respect, the formulations object of the invention can be preferably administered in combination with 3- [4- (2- carboxyethyl-3 , 5-dimethylpyrrol-2-yl)methylidenyl] -2- indolinone and 3 [ (2 , 4-dimethylpyrrol-5-yl)methylidenyl] -2- indolinone, better known as Sugen SU 6668 and SU 5416, respectively . The formulations of the invention may be administered sequentially with known anticancer agents when a combination formulation is inappropriate.
Therefore, it is a further object of the present invention a product containing a formulation for parenteral use of estramustine phosphate in admixture with human albumin, wherein the weight ratio between estramustine phosphate and human albumin is from about 1:5 to about 1:0.3, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy .
Toxicology
To study the local irritant effects of estramustine phosphate after repeated intravenous administrations to rats, in comparison to a formulation of estramustine phosphate according to the present invention, the active was dissolved in different vehicles such as water solution for injection and water solution for injection further containing different amounts of human albumin. In particular, the following solutions of estramustine phosphate : human albumin in a weight ratio of 1:3.3 and of 1:0.8, were prepared and tested.
Male Sprague-Dawley rats were used because of their acceptance as a predictor of toxic change in man. The rats were 6 weeks old at the start of the study.
Estramustine phosphate, in the form of meglumine salt, was administered to groups of rats as a repeated intravenous injection during 3 days. Rats were then sacrificed: a half of the rats at the fourth day and a half at the fifth day. The dose level of estramustine phosphate, in all the different tested solutions, was of 150 mg/kg/day. Clinical observations were recorded daily. Thrombophlebitic side effects resulted in a dark bluish/blackish coloration of the tail during the treatment period.
A score system based on tail coloration and its extension was used to evaluate the different tested formulations. The score system considered estramustine phosphate water solution as the positive control (i.e. marked toxicity) . Water for injection was administered to the control group as negative control (i.e. no toxicity signs).
Histological evaluation was carried out on the tail of the rats treated with the composition of the invention.
Estramustine phosphate in a water solution induced, at the used dose, local irritant effects at the injection site after the first administration and marked toxicity signs at the end of the experiment.
Albumin containing formulations, according to the present invention, showed no toxicity signs even when albumin was present at very low concentrations. Histological evaluation of the tail of the rats treated with the formulations containing albumin did not reveal any damage when compared to the tails of the control group.
It was thus concluded that estramustine phosphate in a water solution containing human albumin, according to the present invention, induced markedly less local irritant effects when compared with a water solution of the same. One particularly preferred schedule for administering the formulation of estramustine phosphate according to the invention is a single infusion given once weekly to a maximal dose of 4000 mg or 3500 mg/m2.
Another preferred schedule is the administration of a single drug infusion once every two to four weeks . One schedule may be preferred over another in consideration of schedules with other optional concomitant therapy. These schedules may repeat in serial or as repetitive fashion.
The formulations of the present invention are useful in antitumor therapy, particularly in the treatment of prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer and cancers of the brain.
The formulations object of the present invention are prepared according to conventional techniques adopted in the preparation of pharmaceutical forms for parenteral use. Typically, a proper amount of estramustine phosphate, either as a dry powder or into a lyophilised form, is dissolved in a pharmaceutically acceptable solution for parenteral use and then admixed with a proper amount of human albumin, either as a dry powder or as a commercially available solution, e.g. human albumin 25%, 20% or 5%, optionally properly diluted.
As an example, a proper amount of estramustine phosphate in the form of a suitable salt such as, for instance, N-methyl glucamine salt, is dissolved in a suitable amount of sterile water or aqueous dextrose solution, e.g. 5% dextrose in water for intravenous administration, and then admixed with a proper amount of powdered human albumin. The above admixture is then stirred, sterilised, and subsequently lyophilised according to conventional techniques . The freeze-dried formulation is prepared and stored in vials for injection; the addition of a proper amount of sterile water or of a physiological solution for parenteral use enables the preparation of the final formulation to be injected.
Alternatively, a proper amount of estramustine phosphate, for instance as N-methyl-glucamine salt and under lyophilized form, is added to a proper amount of water or of a physiological solution for parenteral use already containing human albumin.
In such a way, the preparation of the final formulation to be injected is prepared just before its use, by reconstituting the lyophilized form containing the active principle, for instance estramustine phosphate N-methyl- glucamine salt, in the presence of a physiological solution for parenteral use containing a proper amount of human albumin.
It is therefore a further object of the invention a product comprising estramustine phosphate or salts thereof, under lyophilized form, and a physiological solution for parenteral use containing human albumin.
The above methods are also suitable for preparing high dosages estramustine phosphate formulations whilst maintaining the desired weight ratio between the components .
The unit strength of the formulation to be injected depended on the concentration of the active in the solution itself and, of course, on the filling volume of the vials used to prepare the final formulation.
Additionally, the formulations of the present invention may optionally contain pharmaceutically acceptable excipients for parenteral administration such as, for instance, bulking agents, e.g. lactose or mannitol, pH buffering agents, anti-oxidant agents, preservative agents, tonicity adjusters and the like. The following examples are herewith intended to better illustrate the present invention without representing any limitation to it.
Example 1 Preparation of estramustine phosphate:albumin=l: 3.3 weight ratio Estramustine phosphate (300 mg) were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. N-methyl-glucamine (120.8 mg) was then added under stirring to the watery dispersion of the active and, after a few minutes, a clear solution was obtained. 4 ml of a commercially available solution of human albumin at 25% concentration were added whilst maintaining the solution under stirring.
The obtained solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 100 mg/ml of human albumin (1:3.3 weight ratio respectively).
A solution prepared as previously described, properly sterilized by filtration, was tested for its local vein tolerability in rats.
Example 2
The formulation described in Example 1 was also prepared by dissolving the commercially available Estracyt® freeze- dried formulation containing 300 mg/vial of the active. The reconstitution of the formulation was made by using 10 ml of a 100 mg/ml human albumin solution so as to obtain a final concentration of 30 mg/ml of estramustine phosphate and 100 mg/ml of human albumin (1:3.3 weight ratio respectively) .
The albumin solution could be prepared either by dissolving in water a proper amount of human albumin as a dry powder or by properly diluting a commercially available human albumin solution. Example 3 Preparation of estramustine phosphate : albumin=l : 0.8 weight ratio 300 mg of estramustine phosphate were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 120.8 mg of N-methyl-glucamine were then added under stirring to the watery dispersion of the active and, after a few minutes, a clear solution was obtained. 1 ml of a commercially available solution of human albumin at 25% concentration was added whilst maintaining the solution under stirring.
The obtained solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 25 mg/ml of human albumin (1:0.8 weight ratio respectively).
A solution prepared as previously described, properly sterilized by filtration, was tested for its local vein tolerability in rats.
Example 4 The formulation described in Example 3 was also prepared by dissolving the commercially available Estracyt® freeze- dried formulation containing 300 mg/vial of the active. The reconstitution of the formulation was made by using 10 ml of a 25 mg/ml human albumin solution so as to obtain a final concentration of 30 mg/ml of estramustine phosphate and 25 mg/ml of human albumin (1:0.8 weight ratio respectively) . The albumin solution could be prepared either by dissolving in water a proper amount of human albumin as a dry powder or by properly diluting a commercially available human albumin solution.

Claims

1. A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent and estramustine phosphate in admixture with human albumin, wherein the weight ratio of estramustine phosphate to human albumin is from about 1:5 to about 1:0.3, respectively.
2. A formulation according to claim 1 wherein the weight ratio of estramustine phosphate to human albumin is from about 1:4 to about 1:0.4, respectively.
3. A formulation according to claim 1 or 2 wherein the weight ratio of estramustine phosphate to human albumin is from about 1:1 to about 1:0.5, respectively.
4. A formulation according to any one of the preceding claims which is in single infusion dosage form comprising at least 1300 mg of the estramustine phosphate.
5. A formulation according to any one of the preceding claims which is in single infusion dosage form comprising at least 950 mg/m2 of the estramustine phosphate .
6. A formulation according to any one of the preceding claims for intravenous use.
7. A formulation according to any one of the preceding claim wherein the estramustine phosphate is in the form of a pharmaceutically acceptable salt for intravenous use.
8. A formulation according to any one of the preceding claims wherein the estramustine phosphate is in the form of N-methyl glucamine salt.
9. A formulation according to any one of the preceding claims for use in the treatment of cancer.
10. A formulation according to claim 9 wherein the cancer is prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer or cancer of the brain.
11. A product which comprises
(i) a pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent and estramustine phosphate in admixture with human albumin, wherein the weight ratio of estramustine phosphate to human albumin is from about 1:0.5 to about 1:0.3, respectively, and (ii) one or more chemotherapeutic agents; as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
12. A product according to claim 11 wherein the chemotherapeutic agent, optionally present within liposomal formulations, is selected from taxane, taxane derivatives, CPT-11, camptothecin and derivatives thereof, doxorubicin, idarubicin, epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin, Sugen SU 5416 and Sugen SU 6668.
13. A product according to claim 11 for intravenous use.
14. A product according to claim 11 for use in the treatment of prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancers or cancers of the brain.
15. A formulation according to claim 6 for use in suppressing or reducing the side-effects associated with the intravenous administration of estramustine phosphate and pharmaceutically acceptable salts thereof .
16. A formulation according to claim 15 wherein the side effects comprise ulcerative lesions and thrombophlebitis at the site of injection.
17. A product comprising estramustine phosphate or pharmaceutically acceptable salts thereof, in the form of a lyophilised powder, and a physiological solution for parenteral use comprising human albumin.
18. Use, in the manufacture of a medicament for parenteral administration, of estramustine phosphate in admixture with human albumin, wherein the weight ratio of estramustine phosphate to human albumin is from about 1.5 to about 1:0.3.
19. Use according to claim 18 wherein the medicament is for intravenous administration.
PCT/EP2000/007678 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin WO2001010446A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IL14774500A IL147745A0 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin
EA200200234A EA200200234A1 (en) 1999-08-09 2000-08-03 PREPARATIONS FOR PARENTERAL APPLICATION OF ESTRAMUSTINES OF PHOSPHATE AND ALBUMIN
AU62809/00A AU6280900A (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin
JP2001514963A JP2003506408A (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin
KR1020027001700A KR20020019967A (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin
MXPA02001395A MXPA02001395A (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin.
HU0202645A HUP0202645A3 (en) 1999-08-09 2000-08-03 Fornulations for parenteral use of estramustine phosphate and albumin
SK178-2002A SK1782002A3 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin
EP00949471A EP1206266A2 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin
CA002380312A CA2380312A1 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin
BR0013276-4A BR0013276A (en) 1999-08-09 2000-08-03 Pharmaceutical formulation for parenteral use comprising estramustine phosphate as active ingredient
NZ517632A NZ517632A (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin
NO20020631A NO20020631D0 (en) 1999-08-09 2002-02-08 Formulations for parenteral use of estramustine phosphate and albumin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9918779.1A GB9918779D0 (en) 1999-08-09 1999-08-09 Formulations for parenteral use of estramustine phosphate and albumin
GB9918779.1 1999-08-09
ITMI99A001998 1999-09-27
IT1999MI001998 IT1313629B1 (en) 1999-09-27 1999-09-27 New pharmaceutical compositions comprising estramustine phosphate and human albumin, useful for treating cancer e.g. prostate, breast, lung, pancreatic, colorectal, ovarian or brain cancer or melanoma

Publications (2)

Publication Number Publication Date
WO2001010446A2 true WO2001010446A2 (en) 2001-02-15
WO2001010446A3 WO2001010446A3 (en) 2001-05-25

Family

ID=26315835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007678 WO2001010446A2 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin

Country Status (17)

Country Link
EP (1) EP1206266A2 (en)
JP (1) JP2003506408A (en)
KR (1) KR20020019967A (en)
CN (1) CN1511037A (en)
AU (1) AU6280900A (en)
BR (1) BR0013276A (en)
CA (1) CA2380312A1 (en)
CZ (1) CZ2002376A3 (en)
EA (1) EA200200234A1 (en)
HU (1) HUP0202645A3 (en)
IL (1) IL147745A0 (en)
MX (1) MXPA02001395A (en)
NO (1) NO20020631D0 (en)
NZ (1) NZ517632A (en)
PL (1) PL353406A1 (en)
SK (1) SK1782002A3 (en)
WO (1) WO2001010446A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100426450B1 (en) * 2002-03-16 2004-04-13 박래옥 Anticancer Composition Comprising Citric acid, Albumin And Zinc
JP2006524632A (en) * 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド Composition and method of drug delivery
WO2007134595A2 (en) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg Novel formulation, oriented to tumour physiology, of a cytostatic, in particular of cis-platinum
US7595293B2 (en) 2003-04-11 2009-09-29 Novo Nordisk A/S Stable pharmaceutical compositions
US7794748B2 (en) 2003-01-31 2010-09-14 Yamanouchi Pharmaceutical Co., Ltd. Stable oral solid drug composition
US9364772B2 (en) 2003-04-08 2016-06-14 Novo Nordisk A/S Regeneration of chromatographic stationary phases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002270A1 (en) * 1982-12-13 1984-06-21 Leo Ab Microfine particles having target-seeking properties
WO1998051282A1 (en) * 1997-05-13 1998-11-19 Imarx Pharmaceutical Corp. Solid porous matrices and methods of making and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002270A1 (en) * 1982-12-13 1984-06-21 Leo Ab Microfine particles having target-seeking properties
WO1998051282A1 (en) * 1997-05-13 1998-11-19 Imarx Pharmaceutical Corp. Solid porous matrices and methods of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARTMUT SCHUTZ ET AL.: "ESTRAMUSTIN I.V.:OPTIMALE APPLIKATIONSWEISE ZUR VERH]TUNG VON VENENWANDSCH[DEN" KRANKENHAUSPHARMAZIE, vol. 9, no. 3, - 1988 XP002157640 cited in the application *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100426450B1 (en) * 2002-03-16 2004-04-13 박래옥 Anticancer Composition Comprising Citric acid, Albumin And Zinc
JP2006524632A (en) * 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド Composition and method of drug delivery
US7794748B2 (en) 2003-01-31 2010-09-14 Yamanouchi Pharmaceutical Co., Ltd. Stable oral solid drug composition
US9364772B2 (en) 2003-04-08 2016-06-14 Novo Nordisk A/S Regeneration of chromatographic stationary phases
US7595293B2 (en) 2003-04-11 2009-09-29 Novo Nordisk A/S Stable pharmaceutical compositions
WO2007134595A2 (en) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg Novel formulation, oriented to tumour physiology, of a cytostatic, in particular of cis-platinum
DE102006024528A1 (en) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg New formulation of a cytostatic, especially cis-platin, oriented on tumor physiology
WO2007134595A3 (en) * 2006-05-23 2008-10-16 Albupharm Heidelberg Gmbh & Co Novel formulation, oriented to tumour physiology, of a cytostatic, in particular of cis-platinum

Also Published As

Publication number Publication date
PL353406A1 (en) 2003-11-17
HUP0202645A3 (en) 2004-06-28
JP2003506408A (en) 2003-02-18
NO20020631L (en) 2002-02-08
SK1782002A3 (en) 2002-05-09
CA2380312A1 (en) 2001-02-15
NZ517632A (en) 2004-02-27
HUP0202645A2 (en) 2002-12-28
BR0013276A (en) 2004-08-03
CZ2002376A3 (en) 2002-06-12
CN1511037A (en) 2004-07-07
IL147745A0 (en) 2002-08-14
MXPA02001395A (en) 2002-08-12
KR20020019967A (en) 2002-03-13
AU6280900A (en) 2001-03-05
WO2001010446A3 (en) 2001-05-25
EA200200234A1 (en) 2002-06-27
NO20020631D0 (en) 2002-02-08
EP1206266A2 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
EP1214078B1 (en) Formulations for parenteral use of estramustine phosphate and amino acids
WO2001010446A2 (en) Formulations for parenteral use of estramustine phosphate and albumin
US6730664B1 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
AU777763B2 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
ZA200201955B (en) Formulations for parenteral use of estramustine phosphate and albumin.
US20040014729A1 (en) Use of estramustine phosphate in the treatment of bone metastasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 147745

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2002-376

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2380312

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1782002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020027001700

Country of ref document: KR

Ref document number: 008114420

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001395

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 62809/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000949471

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 517632

Country of ref document: NZ

Ref document number: 200200234

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/358/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002/01955

Country of ref document: ZA

Ref document number: 200201955

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 1020027001700

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10048463

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000949471

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-376

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 517632

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517632

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000949471

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2002-376

Country of ref document: CZ